Monday, June 1, 2009 | Oncolink

Oncolink Features

Find My Cancer Drug

A phase III comparison of prophylactic cranial irradiation versus observation in patients with locally advanced non-small cell lung cancer: Initial analysis of Radiation Therapy Oncology Group 0214 Presenter: Elizabeth M. Gore, MDPresenter's Affiliation: Medical College of WisconsinType of Session: ScientificBackground Central nervous system (CNS) failure rates are high in patients with locally advanced non-small cell lung cancer. ...
Final results of the phase III, randomized, double-blind AVOREN trial of first-line bevacizumab (BEV) + interferon-?2a (IFN) in metastatic renal cell carcinoma (mRCC) Presenter: B.J. Escudier, et al.Presenter's Affiliation: Institut Gustave Roussy, Villejuif, FranceType of Session: ScientificBackground Renal cell carcinoma (RCC) is diagnosed in more than 120,000 patients in the United States and Europe every...
First results of a phase III multi-centre randomized controlled trial of intensity modulated vs. conventional radiotherapy in head and neck cancer: PARSPORT (CRUK/03/005) Presenter: Christopher NuttingPresenter's Affiliation: On behalf of the PARSPORT Trial Management Group, Cancer Research UKType of Session: ScientificBackground Randomized trials have resulted in relatively good cure rates with combination...
Neuroprotective effect of paroxetine hydrochloride among 781 cancer patients receiving chemotherapy: A URCC CCOP study Presenter: Pascal Jean-Pierre, PhD, MPHPresenter's Affiliation: University of Rochester Medical CenterType of Session: ScientificBackground A large number of cancer survivors, ranging from 17-75% in various studies, report difficulties with...
Phase I study of infusion of HER2/neu (HER2) specific T cells in patients with advanced-stage HER2 overexpressing cancers who have received a HER2 vaccine Presenter: M.L. Disis, L. G. Salazar, A. Coveler, J. Waisman, D. Higgins, J. Childs, N. Bates, Y. DangPresenter's Affiliation: University of Washington, Seattle, WA; Breastlink, Los Angeles, CAType of Session: ScientificBackground HER2/neu...
RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC) Presenter: N. J. RobertPresenter's Affiliation: US Oncology GroupType of Session: ScientificBackground Bevacizumab (B) is a humanized monoclonal antibody which inhibits VEGF, a known central mediator of angiogenesis. Two previous large...
Routine Preventive Care and Cancer Surveillance in Long-Term Survivors (LTS) of Colorectal Cancer: Results from NSABP Protocol LTS-01 Presenter: Hiroko Kunitake, MDPresenter's Affiliation: David Geffen School of Medicine at UCLAType of Session: ScientificBackground Over 11 million cancer survivors currently reside in the United States, and this number is estimated to continue to...
Second malignant neoplasms among survivors of pediatric Hodgkin disease treated with low-dose radiation (15-25.5 Gy) and chemotherapy Presenter: M.M. O'BrienPresenter's Affiliation: Standford UniversityType of Session: ScientificBackground There has been a steady improvement in the survival rates of pediatric patients with Hodgkin's disease as more effective treatment and...
Sexual function in male lymphoma survivors in relationship to age, gonadal hormones and psychosocial issues, and compared to matched controls Presenter: Cecilie E. KiserudPresenter's Affiliation: The Norwegian Radium Hospital, Oslo, NorwayType of Session: ScientificBackground As improved cancer screening and treatments continue to result in higher rates of cancer survival, issues of...
Surveillance and screening for new neoplasms in adult survivors of childhood cancer: A report from the Childhood Cancer Survivor Study (CCSS) Presenter: Paul Nathan, MD, MScPresenter's Affiliation: The Hospital for Sick Children, Toronto, CanadaType of Session: ScientificBackground Series of clinical trials in pediatric oncology, examining outcomes in multiple disease sites, have...
Updated survival analysis of JBR.10: A randomized phase III trial of vinorelbine/cisplatin versus observation in completely resected stage IB and II non-small cell lung cancer (NSCLC) Presenter: M.D. Vincent, C. Butts, L. Seymour, K. Ding, B. Graham, P. Twumasi-Ankrah, D. Gandara, J. Schiller, M. Green, F. Shepherd.Presenter's Affiliation: London Regional Cancer Program, London, ON, CanadaType of Session: ScientificBackground ...